FDA approves warfarin labeling change

Aug 16, 2007

The U.S. Food and Drug Administration has approved a labeling change for the widely used blood-thinning drug Coumadin (warfarin).

The Bristol-Myers Squibb Co. of Princeton, N.J., the manufacturer of Coumadin -- as well as manufacturers of warfarin, the generic version of the drug -- will add information to labels explaining a person's genetic makeup might influence how they respond to the drug. Research has shown a person's response to warfarin depends on variants of the genes CYP2C9 and VKORC1.

The FDA said the labeling change highlights the opportunity for healthcare providers to use genetic tests to improve their initial estimate of what is a reasonable warfarin dose for individual patients.

It's estimated about 2 million people start taking warfarin in the United States every year to prevent blood clots, heart attacks and stroke. Warfarin is a difficult drug to use because people taking a dose larger than they can tolerate are at risk of life-threatening bleeding. Those who receive too low a dose are at risk of equally dangerous blood clots.

Warfarin is the second most common drug -- after insulin --implicated in U.S. emergency room visits for adverse drug events.

Copyright 2007 by United Press International

Explore further: Pediatric infectious disease expert sheds light on vaccine myths

Related Stories

Things to know about new water rules in California drought

58 minutes ago

Brown lawns, dusty cars and idle sprinklers loom this summer under Gov. Jerry Brown's mandate to reduce urban water use by 25 percent to get through the drought. The State Water Resources Control Board approved ...

Rare birds jammed inside water bottles in Indonesia

1 hour ago

Indonesian police have arrested a suspected wildlife smuggler after discovering nearly two dozen rare birds, mostly yellow-crested cockatoos, jammed inside plastic water bottles in his luggage.

Recommended for you

GlaxoSmithKline opts to hold on to HIV business

10 hours ago

British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

FDA petitioned to stop sales of essure implant

May 05, 2015

(HealthDay)—Bayer's contraceptive implant Essure can cause serious complications and should be taken off the market, says a citizen's petition filed with the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.